{"id":2425,"date":"2016-11-01T12:01:00","date_gmt":"2016-11-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/nichtsteroidale-antiphlogistika-und-herzinsuffizienz"},"modified":"2016-11-01T12:01:00","modified_gmt":"2016-11-01T11:01:00","slug":"nichtsteroidale-antiphlogistika-und-herzinsuffizienz","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2016\/nichtsteroidale-antiphlogistika-und-herzinsuffizienz","title":{"rendered":"Nichtsteroidale Antiphlogistika und Herzinsuffizienz"},"content":{"rendered":"<p>\u00dcber die kardiovaskul\u00e4ren Nebenwirkungen nichtsteroidaler Antiphlogistika (NSAID; (unselektive und selektive COX-2-Hemmer) haben wir in den vergangenen Jahren mehrfach berichtet (1). Neben akuten Koronarsyndromen, Schlaganf\u00e4llen, hypertensiven Krisen und pl\u00f6tzlichen Todesf\u00e4llen ist die Einnahme von NSAID auch mit dem Auftreten einer Herzinsuffizienz assoziiert. Das Risiko f\u00fcr eine manifeste Herzinsuffizienz erh\u00f6ht sich unter NSAID-Therapie nach einer Metaanalyse aus [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00dcber die kardiovaskul\u00e4ren Nebenwirkungen nichtsteroidaler Antiphlogistika (NSAID; (unselektive und selektive COX-2-Hemmer) haben wir in den vergangenen Jahren mehrfach berichtet (1). Neben akuten Koronarsyndromen, Schlaganf\u00e4llen, hypertensiven Krisen und pl\u00f6tzlichen Todesf\u00e4llen ist die Einnahme von NSAID auch mit dem Auftreten einer Herzinsuffizienz assoziiert. Das Risiko f\u00fcr eine manifeste Herzinsuffizienz erh\u00f6ht sich unter NSAID-Therapie nach einer Metaanalyse aus [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2407,1859,4788,1900,611,1368,180,502,626,627,4791,408,4790,680,564,562,4789,563,565,673,1858,2237,2585,3783],"class_list":["post-2425","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acemetacin","tag-celecoxib","tag-cnt-studie","tag-dexibuprofen","tag-diclofenac","tag-etoricoxib","tag-herzinsuffizienz","tag-ibuprofen","tag-indometacin","tag-indomethacin","tag-ketorolac","tag-meloxicam","tag-nabumeton","tag-naproxen","tag-nichtsteroidale-antiphlogistika","tag-nichtsteroidale-antirheumatika","tag-nimesulid","tag-nsaid","tag-nsar","tag-piroxicam","tag-rofecoxib","tag-sos-studie","tag-sulindac","tag-valdecoxib"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2425"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2425\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}